Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

CVS Health

Elevance Health Inc

The first major U.S. health insurers have agreed to start paying for the popular anti-obesity drug Wegovy for certain people on Medicare with heart-related conditions.

First Medicare Health Plans to Start Paying for Weight-Loss Drug Wegovy

Broadcom

As the stock market rally continues, the trillion-dollar market cap club stands to get just a bit more crowded. Undoubtedly, more than a handful of mega-cap titans could pass the $1 trillion milestone as soon as 2024.

Knocking on the Trillion-Dollar Door: 3 Stocks Ready to Shatter the Market Cap Milestone

Some large health insurers in the U.S. will start covering Wegovy, which has become a popular anti-obesity drug — but not for those using it to lose weight, according to a report by The Wall Street Journal.

Wegovy will be covered by some insurers, but not for weight loss: report

Intuitive Surgical

UnitedHealth Group

Barron's published an article in February discussing cheap healthcare stocks to buy, noting comments from Janus Henderson Global Life Sciences (MUTF: JAGLX ) co-manager Andy Acker. “At one point in October [2023], we had 232 biotech companies trading below the levels of cash on their balance sheet,” Acker told Barron's.

3 Healthcare Stocks to Buy From 3 of the Best Actively Managed Funds

Altimmune

Amgen

Eli Lilly

Madrigal Pharmaceuticals

Rhythm Pharmaceuticals

Viking Therapeutics

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are answering the urgent need for effective solutions with a new generation of weight loss drugs capable of achieving previously unattainable levels of weight reduction.

7 Stocks That Will Drive the Weight Loss Drugs Market

Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the “outrageously high price has the potential to bankrupt Medicare, the American people and our entire health care system.

Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy

Researchers found Novo Nordisk's Ozempic could be manufactured for an estimated 89 cents to $4.73 for a month's supply, figures that include a profit margin.

Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests

The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the dominance of Novo Nordisk and Eli Lilly is unlikely to be toppled anytime soon.

Here's Why Ozempic And Mounjaro Rivals Won't Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon

FedEx

Zoom Video

As we approach the end of the year's first quarter, the stock market has enjoyed a strong run. Three months into 2024 and the benchmark S&P 500 index is already up 10%.

3 Stocks to Buy for the Next Bull Run: March 2024

Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.

Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline

NVIDIA

Novo Nordisk and Nvidia are collaborating on a new computing center. It'll be located in Denmark, and devoted to biomedical research.

Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy?

Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the way.

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

Novo Nordisk (NVO) closed the most recent trading day at $129.05, moving +0.23% from the previous trading session.

Why the Market Dipped But Novo Nordisk (NVO) Gained Today

Novo Nordisk AS (NVO), maker of the weight-loss drug Wegovy, is set to acquire Cardior Pharmaceuticals, a German drug company, in a deal for up to 1.025 billion euros ($1.11 billion).

Novo Nordisk Buys Heart Disease Drug Maker Cardior in $1.11 Billion Deal

Novo Nordisk is one of the leading drugmakers in the world, developing hit medications such as Ozempic. The company is using artificial intelligence (AI) to process larger volumes of data from clinical trials.

Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market

Novo Nordisk said it plans to seek coverage by Germany's public health insurance scheme for the use of its Wegovy drug to cut the risk of strokes and heart attacks, if the drug's extended indication wins European approval.

Novo ready to seek German insurance coverage of Wegovy for heart use

NEW YORK--(BUSINESS WIRE)--Actylis and Novo Nordisk Pharmatech A/S have entered into an agreement for the distribution of pharmaceutical grade Benzalkonium Chloride (BKC) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland. By combining Novo Nordisk Pharmatech's leading position as a manufacturer of the highest standards of pharmaceutical grade quaternary ammonium compounds (Quats), with Actylis' expertise and infrastructure in critical raw material dist.

Actylis and Novo Nordisk Pharmatech Announce a Strategic Partnership for the Distribution of Benzalkonium Chloride in Targeted European Countries.

Novo Nordisk, the Danish pharmaceutical whose market cap has swelled due to popular weight loss drugs, on Monday announced it was making an acquisition targeting cardiovascular disease.

Novo Nordisk targets heart disease in $1.1 billion deal

Demand for obesity and diabetes treatments such as Ozempic, Mounjaro, and Wegovy is off the charts. Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and diabetes.

Novo Nordisk and Eli Lilly May Finally Have Some Real Competition

Denmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline.

Novo Nordisk to buy Cardior Pharmaceuticals for up to $1.1 bln

Bagsværd, Denmark, and Han n over, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved.

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

Novo Nordisk's Articles of Association 2024 Attachment Articles of Association 21 Mar 2024

Novo Nordisk A/S - Articles of Association 2024

Two of the year's biggest investment themes, artificial intelligence and anti-obesity drugs, are finally meeting up, as Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ: NVDA announced a partnership to develop supercomputers.

Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer

Some patients are willing to pay more for GLP-1 weight loss drugs like Wegovy than others — and it's strongly correlated to their annual income.

Here's how much people are willing to spend on weight loss drugs, according to a new survey

Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.

News for Novo Nordisk Stock (NVO)